Switch Therapeutics
Craig is an experienced scientist and leader in the field of drug discovery, with expertise across multiple drug modalities including RNA and protein therapies. Craig led a drug discovery department at Genentech and played a leading role developing the RNA
therapeutic and delivery strategy. In addition to his experience in onboarding new modalities, he also has expertise in drug development of protein-based therapeutics across a broad range of therapeutic areas. Prior to joining Genentech, Craig was a staff
scientist in the Biological Sciences Department at Lawrence Livermore National Laboratories and led a team to build multiple vaccine programs using novel nanoparticle technology. He holds a Ph.D. in Biophysics from the University of California, Davis and a B.S. in Biology and Physics from Vassar College.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.